Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — Q2 2017 Earnings Presentation

10 slides from Lumos Pharma's earnings presentation, Jul 28, 2017

  1. Slide 1: Second Quarter 2017 Results

    NewLink Genetics Corporation Nasdaq: NLNK July 28, 2017 Second Quarter 2017 Results

  2. Slide 2: Agenda

    Agenda 2 Introduction  Jack Henneman, Executive Vice President & CFO IDO Pathway Program Developments  Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates / Guidance on Timing of Data  Eugene P. Kennedy, M.D., Vice President Clinical & Medical Affairs Second Quarter 2017 Financial Re

  3. Slide 3: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, w

  4. Slide 4: Highlights

    Highlights  Clinical data continue to support indoximod as a potent IDO pathway inhibitor with the potential to improve outcomes for patients with cancer when used in combination with other cancer therapies  Progress toward initiation of a pivotal trial with indoximod for patients with advanced me

  5. Slide 5: Allowed US Patent for Indoximod Formulation (Salt): Potential Market Exclusivity in Advanced Melanoma

    Allowed US Patent for Indoximod Formulation (Salt) 5 Potential Market Exclusivity In Advanced Melanoma 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Initiate Pivotal Melanoma Potential US Launch Original US Patent** Expiration Potential EU Launch

  6. Slide 6: Indoximod plus Provenge (sipuleucel-T) Vaccine

    Indoximod plus Provenge (sipuleucel-T) Vaccine  46 Patients: Indoximod (22) vs Placebo (24)  PA2024 ELISPOT response data showed no statistically significant difference*  Statistically significant improvement in radiographic progression free survival (rPFS) – Median rPFS of 10.3 months for indoxi

  7. Slide 7: Indoximod plus Standard of Care Chemotherapy in AML

    Indoximod plus Standard of Care Chemotherapy 7 Phase 1/2 Evaluating the Feasibility of Combination with 7+3 Regimen Strong preclinical data and significant unmet need Acute Myeloid Leukemia (AML)  Patients with newly diagnosed AML  Surrogate efficacy endpoint being explored as potential fast to ma

  8. Slide 8: Clinical Introduction: Indoximod (Salt) Formulation

    Clinical Introduction: Indoximod (Salt) Formulation 2H 2017: Phase 1b for patients with AML 2H 2017: Healthy volunteers Q4 2017: Dose escalation phase of pivotal trial 8

  9. Slide 9: Second Quarter 2017 Financial Results

    Second Quarter 2017 Financial Results Cash and Equivalents $107.8 million Debt ~$0.4 million YE 2017 Cash (Projected) ~$75 million Forecast Quarterly Negative Cash-Flow1 ~$14 million Shares Outstanding 29.2 million Market Capitalization ~$210 million Headcount2 72 9 1 Excludes the proceeds from any

  10. Slide 10: Q & A

    10 Q & A

NewLink Genetics — Q2 2017 Earnings Presentation on 6ix